Faeth Therapeutics Inc (FTH): Next-Year EPS Estimate 72.99%
As of 2026-08-05, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 72.99%. Featured in 4 EPS revision reports, most recently on 2026-06-25.
On 2026-08-05, analyst consensus for FTH's next-year EPS growth shifted from 88.60% to 72.99% — a negative change of 15.61 percentage points. Current-year growth is projected at 22.02%.
What's Driving This
The primary structural driver of Faeth Therapeutics’ rise is the upward revision to its next-year EPS growth estimate, which analysts trimmed from 95.08% to 88.67% on 2026-07-28 but remains very high at 88.17%. No recent news headlines are available to connect the move to a specific catalyst such as an earnings beat, contract win, guidance raise, or product launch. The stock’s advance appears to have continued beyond the initial revision, supported by persistently strong consensus growth expectations.
Generated 2026-07-31 from news as of 2026-07-31
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 72.99%
- EPS growth this year
- 22.02%
- EPS next quarter (est)
- -$0.74
- Last price
- $24.59
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-05 | 72.99% | 22.02% | -$0.74 | $24.59 |
| 2026-08-04 | 88.60% | -209.12% | -$2.76 | $25.50 |
| 2026-08-03 | 88.17% | -208.68% | -$2.82 | $27.34 |
| 2026-08-02 | 88.17% | -208.68% | -$2.82 | $27.24 |
| 2026-07-31 | 88.17% | -208.68% | -$2.82 | $27.24 |
| 2026-07-30 | 88.67% | -236.92% | -$2.95 | $28.82 |
| 2026-07-29 | 88.67% | -236.92% | -$2.95 | $28.93 |
| 2026-07-28 | 88.67% | -236.92% | -$2.95 | $29.13 |
| 2026-07-27 | 95.08% | -691.77% | -$3.24 | $29.24 |
| 2026-07-26 | 95.08% | -691.77% | -$3.24 | $28.29 |
| 2026-07-24 | 95.08% | -691.77% | -$3.24 | $28.29 |
| 2026-07-23 | 95.08% | -691.77% | -$3.24 | $27.76 |
| 2026-07-22 | 95.08% | -691.77% | -$3.24 | $28.66 |
| 2026-07-21 | 95.08% | -691.77% | -$3.24 | $28.37 |
| 2026-07-20 | 95.08% | -691.77% | -$3.24 | $28.19 |
| 2026-07-19 | 95.07% | -691.77% | -$3.54 | $25.87 |
| 2026-07-17 | 95.07% | -691.77% | -$3.54 | $25.87 |
| 2026-07-16 | 95.07% | -691.77% | -$3.54 | $25.94 |
| 2026-07-15 | 95.07% | -691.77% | -$3.54 | $31.47 |
| 2026-07-14 | 95.07% | -691.77% | -$3.54 | $33.12 |
| 2026-07-13 | 95.07% | -691.77% | -$3.54 | $33.36 |
| 2026-07-12 | 95.07% | -691.77% | -$3.54 | $36.16 |
| 2026-07-09 | 95.07% | -691.77% | -$3.54 | $32.54 |
| 2026-07-08 | 95.07% | -691.77% | -$3.54 | $28.02 |
| 2026-07-07 | 95.07% | -691.77% | -$3.54 | $26.11 |
| 2026-07-06 | 95.07% | -691.77% | -$3.54 | $24.49 |
| 2026-07-05 | 95.07% | -691.77% | -$3.54 | $22.92 |
| 2026-07-02 | 95.07% | -691.77% | -$3.54 | $22.92 |
| 2026-07-01 | 95.07% | -691.77% | -$3.54 | $23.66 |
| 2026-06-30 | 95.07% | -691.77% | -$3.54 | $25.00 |
Reports Featuring FTH
- 2026-06-25
FTH Surges 69.8% on EPS Revision; LILA, CRMT Also Jump
- 2026-06-24
FTH Leads EPS Revision Rally with 68.9% Surge; CRMT, LILA Also Gain
- 2026-06-23
FTH +65%, CRMT +65% Lead EPS Revision Surge; RFIL +29%, LILA +24%
- 2026-06-22
Top EPS Revision Winners: OTLK Surges 66%, FTH Gains 60% on Estimate Hikes
Recent News
Screen Performance
Aggregate stats across all 1915 tickers our top-EPS-revision screen has flagged over the past 126 days.
- Median return since detection
- +4.1%
- % of tickers in the green
- 57%
- Median return on winners
- +20.8%
- Large revisions captured
- 1269
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Faeth Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-05, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 72.99%, based on analyst consensus.
When was the latest EPS estimate revision for FTH?▾
The most recent revision occurred on 2026-08-05, when analysts adjusted the next-year EPS growth estimate from 88.60% to 72.99%.
What sector and industry does Faeth Therapeutics Inc belong to?▾
Faeth Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. FTH appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Faeth Therapeutics Inc (FTH) appears here because it was detected by our daily top-EPS-revision-performer screen.